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Osteoporosis is a major health issue. It is a disease
characterised by low bone mass and altered bone
architecture leading to an increased susceptibility to
fractures (1).Osteoporosis is deﬁned by a value of
bone mineral density (BMD), measured by dual-
energy X-ray absorptiometry (DXA) on the spine or
hip, more than 2.5 SD below the normal peak values
for young adults (T-score < )2.5) (WHO criteria) or
by the occurrence of a low trauma fracture.
So, BMD measurement is the pivotal mainstay in
the decision to initiate an anti-resorptive treatment.
BMD is used also to monitor treatment efﬁcacy.
However, BMD alone presents some shortcomings,
both for the diagnosis of osteoporosis and for the
treatment monitoring. With regard to diagnosis,
many fractures occur in patients who do not have a
T-score < )2.5. As far as monitoring is concerned,
BMD changes in response to anti-resorptive treat-
ment are slow (2–5% per year, or a maximum of
< 3% in 3–6 months). So, at least 1 year of treat-
ment is necessary before a signiﬁcant change in
BMD can be observed and, furthermore, absence of
BMD increase does not imply absence of therapeutic
response. The changes in bone turnover rate are
much faster and several analytes, which can be mea-
sured easily in serum or urine, reﬂect the rate of
bone formation or bone resorption. These bone
turnover markers (BTM) will be presented here. We
SUMMARY
Objectives: To review the clinical value of bone turnover markers (BTM), to initi-
ate and⁄or monitor anti-resorptive treatment for osteoporosis compared with bone
mineral density (BMD) and to evaluate suitable BTM and changes in BTM levels
for signiﬁcance of treatment efﬁciency. Methodology: Consensus meeting gener-
ating guidelines for clinical practice after review and discussion of the randomised
controlled trials or meta-analyses on the management of osteoporosis in postmen-
opausal women. Results: Although the correlation between BMD and BTM is sta-
tistically signiﬁcant, BTM cannot be used as predictive markers of BMD in an
individual patient. Both are independent predictors of fracture risk, but BTM can
only be used as an additional risk factor in the decision to treat. Current data do
not support the use of BTM to select the optimal treatment. However, they can be
used to monitor treatment efﬁciency before BMD changes can be evaluated. Early
changes in BTM can be used to measure the clinical efﬁcacy of an anti-resorptive
treatment and to reinforce patient compliance. Discussion: Determining a thresh-
old of BTM reﬂecting an optimal long-term effect is not obvious. The objective
should be the return to the premenopausal range and⁄or a decrease at least equal
to the least signiﬁcant change (30%). Preanalytical and analytical variability of
BTM is an important limitation to their use. Serum C-terminal cross-linked telopep-
tide of type I collagen (CTX), procollagen 1 N terminal extension peptide and bone
speciﬁc alkaline phosphatase (BSALP) appear to be the most suitable. Conclusion:
Consensus regarding the use of BTM resulted in guidelines for clinical practice.
BMD determines the indication to treat osteoporosis. BTM reﬂect treatment efﬁ-
ciency and can be used to motivate patients to persist with their medication.
Review Criteria
An extensive Pubmed search was used to identify
the relevant literature, which included randomised
controlled trials and meta-analyses, considering the
use of biochemical markers of bone turnover in
osteoporosis. A critical appraisal of the data was
obtained through consensus expert meetings. The
guidelines for the clinical practice are the
conclusions of these analyses and discussions.
Message for the Clinic
Standardised guidelines deﬁned in the consensus
‘how to use bone turnover markers’ will help
clinicians in a better management of osteoporosis.
As bone turnover markers decrease rapidly after
initiation of anti-resorptive treatment, they
represent useful surrogate markers not only to
reﬂect therapeutic success but also to monitor
patient’s compliance.
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value in the selection of patients to be treated and in
the follow-up of patients undergoing treatment for
osteoporosis.
Methodology
We included randomised controlled trials and meta-
analyses in postmenopausal women, comparing
interventions currently registered in Belgium for the
management of osteoporosis with placebo. The
results had to be reported with a follow-up of at least
1 year. The relevant articles of the literature review
were discussed and a critical appraisal of the data
was obtained through a consensus experts meeting.
The guidelines for clinical practice, phrased as
‘Consensus of the Belgian Bone Club’ (Table 1), are
the conversion of the conclusions of the consensus
expert meeting into daily practice, reviewed by the
members of the Advisory Board on Bone Markers.
Biomarkers of bone turnover
To predict bone loss, we should measure at one
time-point the rate of bone turnover and the balance
between formation and resorption. But, by measur-
ing the concentration of BTM (corresponding to the
ratio of their production and degradation), we can-
not assess quantitatively the amount of matrix
deposited and mineralised or destroyed per unit of
time, even though some BTM are more linked to
bone resorption and others to bone formation.
Bone formation
Bone-speciﬁc alkaline phosphatase
There are several isoforms of alkaline phosphatase
originating from many tissues, mainly liver and bone,
with bone contributing for 40–50% in normal adults.
The bone enzyme can be separated from the other
forms by chemical separative methods such as lectin
precipitation, heat resistance or electrophoresis (2).
Automation of the speciﬁc immunoassays for bone-
speciﬁc alkaline phosphatase (BSALP) has improved
the analytical reproducibility to < 5%. Unfortunately,
there is a signiﬁcant cross-reactivity (± 15%) with the
liver form (3), which can be clinically relevant when
the patient suffers from liver disease. The half-life of
BSALP is 1–2 days, making it less sensitive to circa-
dian variation than other markers with a shorter half-
life. The long-term intra-individual variability of
BSALP is 10%, and this biological variability repre-
sents the major component of variability since the
improvement of analytical methods.
Osteocalcin
Osteocalcin is a small protein synthesised exclusively
by osteoblasts (and odontoblasts). It is deposited into
the bone matrix to form the major non-collagenic part
and can be released in part into the circulation. The
ﬂux of osteocalcin towards the serum also results from
matrix resorption, thus it is not a pure osteoblast
function marker. Osteocalcin has a circadian rhythm
and is higher in the early morning (4). It is excreted
by glomerular ﬁltration and its concentration is
increased when glomerular ﬁltration decreases (5).
Osteocalcin can be measured by several immuno-
assays, but its measurement is complicated by the
presence in variable amount of several fragments, by
a lack of uniform standardisation (6) and by its deg-
radation in the serum even in the absence of haemol-
ysis causing an important preanalytical problem. The
conservation problem can be improved, but only in
part, by using an immunoassay, which recognises a
large N-terminal fragment (7).
Procollagen I extension peptides
Type I collagen is synthesised as a precursor ﬂanked
at its C- and N-termini with extension peptides,
which are cleaved when the collagen is deposited to
form the bone matrix. The catabolism of both exten-
sion peptides, procollagen 1 C terminal extension
peptide and procollagen 1 N terminal extension pep-
tide (P1NP) is under hormonal control, but their
concentration is not dependent of renal function.
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Table 1 Consensus of the Belgian Bone Club regarding
the use of bone turnover markers: in practice
Indication for anti-resorptive therapy:
BMD hip⁄spine: T-score less than )2.5 SD
or low trauma fracture
#
Assess baseline BTM levels: fasting serum
BSALP or CTX or P1NP
#
Day 0 Start bisphosphonate therapy
3 months Control BTM levels: decrease ‡ 30%
If not:
Check compliance
Check if drug is taken properly (for instance,
not with milk or calcium supplement,
or waters rich in calcium)
Drug storage
6 months Control BTM levels: decrease > 30%
+ return to premenopausal state
1 year Reassess BTM
BMD, bone mineral density; BTM, bone turnover markers;
BSALP, bone-speciﬁc alkaline phosphatase; P1NP, procolla-
gen 1 N terminal extension peptide.
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tissues, its contribution to serum extension peptides
is dominant, at least in the absence of any conjunc-
tive disease. Both peptides can be measured by
immunoassay (8,9) and have been shown to follow
the expected variations in bone turnover in different
physiological and pathological conditions. P1NP cir-
culates as a trimer, which is rapidly degraded at 37 ;
recognition of the monomer varies between assays
(10). They follow a circadian rhythm and are higher
in early morning. The intra-individual coefﬁcient of
variation (CV) is 12.4% for P1NP; combining analyt-
ical and biological variability revealed a critical dif-
ference between two successive serial measurements
of 38% (11).
Bone resorption
Acid phosphatase
Osteoclasts produce an acid phosphatase isoenzyme,
which is not inhibited by tartrate [type 5 tartrate resis-
tant acid phosphatase (TRAP)]. Total TRAP, mea-
sured by chemical methods, has long been considered
as a marker of bone resorption. However, total TRAP
is inﬂuenced by enzymes originating from the erythro-
cytes and platelets, and its measurement can be
hampered by circulating inhibitors. Now it can be
measured in serum by immunoassays using an
immunometric format with a precision of 5% (mass
measurement) or 15% (enzyme activity of the cap-
tured protein). A kinetic assay to measure speciﬁcally
type 5b TRAP, a desialylated isoenzyme present only
in osteoclasts and alveolar macrophages, has also been
described, with a CV of 5–10%. Increased type 5
TRAP levels have been described in diseases character-
ised by increased bone resorption, such as primary or
secondary hyperparathyroidism, Paget’s bone disease
or metastatic bone disease. There are few studies on
type 5b TRAP in osteoporosis studies.
Pyridinoline and deoxypyridinoline crosslinks
These crosslinks (aldehyde links between lysine or
hydroxylysine residues) are formed between collagen
molecules and they stabilise the conjunctive tissue.
They are released into the circulation and excreted
into the urine when collagen is catabolised. They
reﬂect only collagen degradation. Deoxypyridinoline
(DPD) is found only in skeletal tissue, but both
crosslinks mainly originate from bone resorption.
When bone metabolism is normal, 50% of the cross-
links are free and 50% bound to peptides (12). The
measurement most representative of true bone
resorption is probably that of the total crosslinks. It
was shown indeed that when high turnover bone dis-
eases were treated with anti-resorptive drugs, there
was only a minimal decrease in the free crosslinks,
while the peptidic forms decreased dramatically with
total crosslinks in between (13). Today most studies
are based on immunoassay measurements, mainly of
the peptidic forms. They follow a circadian rhythm
and are higher in the early morning.
Telopeptides of type I collagen
These peptides are the non-helical region of type 1
collagen where the crosslinks attach. The measured
molecules are either a trimeric carboxyterminal te-
lopeptide (ICTP), which is measured in serum by
radioimmunoassay (14) ICTP or a synthetic peptide
sequence containing the crosslink site which can be
measured in serum or urine [C-terminal crosslinked
telopeptide of type I collagen (CTX)] (15). There are
four isomers of CTX, according to the isomerisation
of the aspartate (native a- and transformed b-CTX)
and to its racemisation (l or d). Both racemisation
and isomerisation increase with tissue age; thus mea-
surement of the different forms could give an insight
into the mean age of bone tissue (with a⁄b higher if
bone turnover is increased). Practically, there are com-
petition assays, which measure the two isomers in the
urine and b-CTX can be measured in the serum with
a sandwich immunoassay. Serum and urine CTX val-
ues are highly correlated. Another assay called NTX
recognises an epitope of the N-terminal telopeptide of
the a-2 chain of collagen I (16). They follow a circa-
dian rhythm and are higher in the early morning.
Prediction of postmenopausal bone
loss using BTM
Postmenopausal oestrogen deﬁciency causes an accel-
eration of bone remodelling. As osteoclasts, responsi-
ble for bone resorption, are triggered by oestrogen
deﬁciency, there is an imbalance in bone formation
and bone resorption leading to bone loss. The loss
resulting from this imbalance is faster in the trabecular
than in the cortical compartment of bone (17,18). The
increase in the parameters of bone resorption varies
from 0% to 150%, with a subsequent increase of 0%
to 100% in markers of bone formation (12,19). The
increased remodelling can persist until late in life (19–
21), more than 30 years postmenopause.
Various longitudinal studies strongly support the
fact that high bone turnover leads to faster bone loss
than normal or low bone turnover (20,22–25). In
one study, using markers such as total serum alkaline
phosphatase, fasting urinary calcium and hydroxy-
proline, women diagnosed as fast losers, based on
markers, had lost 26.6% of bone mass after 12 years
compared with 16.6% in those classiﬁed as slow los-
ers (23). In elderly patients, aged 75 years, signiﬁcant
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serum CTX, TRAP and urinary DPD and the areal
BMD of the leg region, derived from the whole body
measurement (26). No correlation was found with
the areal BMD of the spine. It is well known that
degenerative osteoarthritic changes at the spine can
be a confounding factor for BMD measurements by
DXA. The progressive availability of BTM with a bet-
ter speciﬁcity and precision should increase their
capability to predict the rate of bone loss.
Although the correlation between BMD and the
levels of BTM is statistically signiﬁcant (27,28), it is
not strong enough to use BTM as predictive markers
of BMD in an individual patient.
Fracture risk assessment: BTM
is an independent risk factor
The major complication of osteoporosis is the occur-
rence of fractures for minimal trauma with their
inherent increase in morbidity and mortality. A
decrease in one T-score in BMD, measured by DXA,
is associated with a doubling of the relative risk of
fracture at the spine, hip and forearm (29).
Several studies have shown that some markers of
bone resorption are independent predictors of frac-
tures, especially spine and hip (30–35). In osteopenic
women, the 10-year probability of fracture amounted
to 26% if at least one risk factor was present
(amongst age, elevated BSALP and prior fracture) vs.
6% only in women without any of the three risk fac-
tors (34). Elevated serum CTX levels were associated
with a signiﬁcantly increased risk of osteoporotic
fractures (32,35), but only above a certain threshold,
suggesting that an increased resorption together with
an increased activation frequency (=the appearance
rate of the basic multi-cellular unit – BMU – in a
histology slide) could lead to a more pronounced
fragility of bone superimposed to the fragility already
induced by a low BMD (21).
There was also an association between the eleva-
tion of markers of bone formation and the risk of
fracture (32–34). An increased risk of hip fracture
was observed in ambulatory and institutionalised
elderly women with low levels of undercarboxylated
osteocalcin, an index for a low vitamin K status
(36,37).
Bone turnover markers and BMD predict fracture
risk independently. When both factors are altered,
the fracture risk is more increased than for each of
them considered separately. In the OFELY study,
women suffering from osteodensitometric osteoporo-
sis of the hip combined with an elevated serum CTX
had a relative risk of fractures within 5 years
amounting to 55%. This is signiﬁcantly higher than
the relative risk linked to an isolated low BMD
(39%) or an isolated elevated CTX (25%) (32). It
must be mentioned, however, that the markers can
only be used as an additional risk factor, not as a
surrogate for BMD measurement in the decision to
treat.
Selection of a speciﬁc treatment
Theoretically, a better response to anti-resorptive
treatment should be expected in patients with a high
bone turnover rate. However, current data do not
support the use of BTM to select the optimal treat-
ment, as the relationship between BTM concentra-
tion and response to anti-resorptive treatment is, at
best, weak (38–41).
In a post hoc analysis of the Fracture Intervention
Trial (FIT), there was no relationship between pre-
treatment P1NP, BSALP or serum C-terminal cross-
linked telopeptide of type I collagen (sCTX) and
alendronate efﬁcacy for incident spine fractures among
osteoporotic women (39). Nevertheless, a recent phar-
macoeconomic study (Markov model) concluded that
measurement of BTM has the potential to identify a
subset of postmenopausal women (top BTM quartile),
without osteoporosis by BMD criteria, for whom
alendronate therapy to prevent fracture is cost-effec-
tive [costs per quality adjusted life years (QALY)
gained at 34,000 and 50,000 USD for women aged
70 years with high bone turnover and femoral neck
BMD T-score of )2.0 and )1.5 respectively] (38).
A similar analysis of the risedronate phase III clin-
ical programme showed that the reduction in the
incidence of vertebral fractures was independent of
baseline urinary DPD. However, the number needed-
to-treat (NNT) to avoid one vertebral fracture at
12 months was 15 in the group of patients with high
DPD and 25 in patients with low DPD, an observa-
tion which is not unexpected, based on the inﬂuence
of the prevalent absolute risk on NNT calculation
(40). The authors concluded that although the
reduction in overall fracture risk seems to occur
independent of baseline bone turnover, patients’
stratiﬁcation by pretreatment bone resorption rate
seems to make some sense from a pharmacoeconomic
point of view (40,41).
Early changes of BTM, changes of BMD
and fracture risk
In the Early Postmenopausal Intervention Cohort
study, early postmenopausal women, receiving
alendronate for the prevention of osteoporosis, with
a decrease of 40% for urinary N-terminal telopeptide
of type 1 collagen (uNTX) or 20% for osteocalcin at
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response in spine BMD. In contrast, the poor speci-
ﬁcity and negative predictive value of these percentu-
al cut-offs of BTM changes implied that a change in
uNTX or osteocalcin above the cut-point was a poor
predictor of bone loss during alendronate treatment
(42).
In a smaller cohort of French osteoporotic women,
the authors claimed that after 4 months of alendro-
nate, sCTX and to a lesser extend uNTX, were the best
predictors of a signiﬁcant gain in spine BMD after
1 year of therapy (43).The authors from the FIT con-
cluded that the correlation between early reduction in
bone turnover and long-term fracture reduction dur-
ing alendronate treatment was at least as strong as that
observed with 1-year changes in BMD. For patients
with a decrease of 30% in bone turnover, compared
with those with a decrease of < 30%, the risk of expe-
riencing a fracture at the end of the trial was signiﬁ-
cantly lower for spine and hip (44).
In the risedronate vertebral fracture trial, the rela-
tionship between vertebral fracture risk and changes
from baseline in sCTX and uNTX were not linear
(p < 0.05). There was little further improvement in
fracture beneﬁt below a decrease of 55–60% for
sCTX and 35–40% for uNTX. The authors concluded
that the decrease in bone resorption in patients tak-
ing risedronate accounts for a large proportion of
the reduction in fracture risk but that there may be a
level of bone resorption reduction below which there
is no further fracture beneﬁt (45).
With continuous (2.5 mg daily) or intermittent
(20 mg every other day for 12 doses every 3 months)
oral doses ibandronate which were linked to a signif-
icant reduction in spinal fractures, similar to that
seen with alendronate or risedronate, the rate of
bone turnover was reduced by 50–60%, a magnitude
also within the range observed with the efﬁcacious
oral bisphosphonates (46). For further clinical devel-
opment of ibandronate, even the role of BTM as a
predictor of efﬁcacy was emphasised. Actually, a
pharmacokinetic-pharmacodynamic model, accu-
rately describing the urinary excretion of CTX was
used to select the appropriate once-monthly dose of
ibandronate (47).Clinical studies showing the non-
inferiority and⁄or superiority of the 150 mg monthly
oral regimen on BMD, over the daily 2.5 mg dose,
the dose which previously demonstrated anti-fracture
efﬁcacy (48), conﬁrmed a posteriori the interest of a
pharmacostatistical model based on BTM changes to
predict the effect of a particular dosage of ibandro-
nate on hard end-points (49).
Data from randomised clinical studies of ibandro-
nate, given orally or intravenously, in different doses
and for variable time intervals to women with osteo-
porosis, were examined to explore the relationship
between intermittent bisphosphonate therapy,
changes in bone resorption and fracture risk. The
magnitude of the reduction in the rate of bone
resorption at the end of the drug-free interval, rather
than its ﬂuctuation pattern after bisphosphonate
administration, determines anti-fracture efﬁcacy, pro-
vided that these ﬂuctuations occur within the pre-
menopausal range (50).
Monitoring bisphosphonate treatment
Bisphosphonate therapy inhibits bone resorption and
decreases the rate of bone remodelling. So, BTM can
be used to measure the effect of an anti-resorptive
treatment. However, determining a threshold of
BTM to attain an optimal long-term effect is not
obvious.
Setting objectives
As opposed to the WHO deﬁnition of osteoporosis
on basis of a low BMD, currently unanimously
accepted criteria to categorise low or high bone turn-
over, compared with premenopausal state, are not
available. Furthermore, as for BMD, there is some
overlap between healthy pre- and postmenopausal
women, as well as between osteopenic and osteopo-
rotic populations in the values of bone remodelling
parameters (51).
The objective should be the return of BTM levels
to the premenopausal range. However, half of the
women with osteoporosis have BTM levels within
the premenopausal range. In these patients, the goal
should be a decrease at least equal to the least signiﬁ-
cant change (LSC). It is interesting to underline that
changes in BMD do not explain alone the anti-frac-
ture efﬁciency of treatment: some patients with
unchanged or even decreased BMD may be protected
against fracture. Thus, as for determining fracture
risk, BTM could be complementary to BMD to pre-
dict the anti-fracture efﬁcacy.
Adherence and persistence
In a study testing the impact of monitoring on
adherence and persistence with anti-resorptive treat-
ment, physician’s reinforcement on adherence to
bisphosphonate treatment, using BTM resulted in a
lower incidence of new radiologically determined
vertebral fractures (odds ratio 0.4; 95% CI: 0.2–1.0).
The positive impact of a positive feedback to the
patient (by telling him his BTM levels were
decreased) was only seen when the decrease in BTM
levels was marked (> 30% decrease) (52).
In a randomised controlled trial, monitoring on
adherence to and persistence with anti-resorptive
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of BTM and the supplying of complementary infor-
mation on the importance of compliance for treat-
ment response were compared with no monitoring.
In the monitored group, cumulative adherence to
therapy was increased by 57% (p = 0.04), with a
trend to persist with therapy for 25% longer
(p = 0.07), both compared with no monitoring.
However, feedback on BTM alone or nurse-monitor-
ing alone did not show any difference in adherence
or persistence rates. Nevertheless, adherence at 1 year
was correlated with BMD increase (hip; r = 0.28;
p = 0.01) and percentage change in uNTX
(r = )0.36; p = 0.002) as response to treatment
efﬁcacy (53). We should also be aware that a
negative feedback (by telling there is no reduction
in BTM) could stimulate the patient in his non-
compliance.
Limitations of BTM use: variability
The production of BTM depends not only on the
rate of bone turnover, but also on the skeletal size,
reﬂecting mainly trabecular bone turnover, which is
4 to 5 times more active than cortical bone. A local-
ised bone disease, bed rest and fracture healing can
interfere with values. For urine markers, the expres-
sion as a ratio to creatinine introduces another factor
of variability.
The relationship between the measured concentra-
tion and what happens in the bone differs intra- and
inter-individually. Inter-individual variability is lar-
gely determined by differences in age, gender and
menopausal status.
Analytical variability
With the improvement in analytical methods, partic-
ularly with the introduction of automated immuno-
assays, the analytical CV remains around 5%. The
absence of uniform standardisation still is a concern
and makes it difﬁcult to compare values obtained by
different methods in different laboratories (54). That
is the reason why all measurements for one individ-
ual should be done in the same laboratory. So, the
main source of variability is preanalytical, mostly
sample conservation and biological variability.
Conservation variability
Concerning sample conservation, osteocalcin and
acid phosphatase are the most difﬁcult to handle.
Collagen peptides and alkaline phosphatase are much
more resistant to degradation. Pyridinoline crosslinks
are light sensitive and degraded under the inﬂuence
of intense UV irradiation.
Biological variability
In adults, the main source of undesirable but con-
trollable biological variability is the circadian rhythm,
with higher values in the early morning hours, then
a steep decrease in the morning, to attain a nadir at
the end of the afternoon (55,56). Most markers fol-
low the same pattern, with the exception of alkaline
phosphatase because of its longer half-life. The steep-
est decline during the morning has been described
for serum CTX, but it is attenuated if the patients
remain in the fasting state. Practically, it implies that
the sampling time for measuring bone markers has
to be strictly controlled. There is also a seasonal vari-
ation in bone turnover, due in part to ﬂuctuations of
vitamin D repletion.
Serum vs. urine markers
Many studies have shown that the intra-individual
variability is around 10% for serum markers and
between 15% and 25% for urine markers. So, the
signal to noise ratio is better for serum markers. This
has important consequences for follow up. Indeed, if
a marker is measured once, the conﬁdence interval
of the result is ±1.96 · SD. The LSC, deﬁned as a
difference reﬂecting a real change with a 5% chance
of type 1 error (false-positive), is a change surpassing
2.8 · CV. Thus, for a CV of 10%, a change of at
least 25–30% must be observed for serum markers to
consider that there is a signiﬁcant evolution, while a
change of 40–70% is required for urine markers.
Fortunately, decreases in this order of magnitude are
observed in individual patients with anti-resorptive
therapy. However, one must be aware of the risk of
type 2 error (false-negative), and it must be avoided
to change treatment on the basis of an insufﬁcient
evolution, at least on two sequential measurements
only.
Consensus of the Belgian Bone Club
Choice of markers
• Serum markers do not need correction for glomer-
ular ﬁltration rate; automated technology for mea-
surement available for serum CTX and serum P1NP.
• Osteocalcin not optimal in routine clinical practice
because of its fragility.
• Serum BSAP can be added in patients without liver
problems (less sensitive to circadian rhythm).
• Measurements for one individual must be per-
formed in the same lab using standard procedures;
samples should be taken while fasting and always at
the same time of day.
• There are no data to determine the optimal postin-
take period to take a blood sample for follow-up
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intake seems to have some support, understanding
that it is always the same period in one individual
patient.
Use of markers (pretreatment)
• Baseline BTM levels cannot be the base of anti-
resorptive drug choice, nor do they predict treatment
effect.
• Bone turnover markers are an independent risk
factor of fracture.
Use of markers (follow-up)
• This use relies on the deﬁnition of LSC (around
30% for serum markers and 50–60% for urine mark-
ers).
• Only a decrease higher than the LSC can be inter-
preted as showing a biological effect.
• Early changes in BTM (baseline vs. posttreatment)
show a biological effect of the medication, proving
patient compliance and persistence.
• The early decrease in BTM level is probably predic-
tive of bone gain and anti-fracture efﬁcacy. However,
it is not known to which level BTM should be
decreased to optimise anti-fracture efﬁcacy.
• As we cannot link BTM decrease to a threshold,
using premenopausal range seems a rational objective
to achieve.
1 The levels of osteoporotic patients whose BTM
levels are still in premenopausal range must still
decrease by 30%.
2 Premenopausal ranges have been well deﬁned.
3 Analytical differences must be resolved by using
the same lab for one individual patient.
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